LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "human trial" as a keyword



Photo by nci from unsplash

A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)

Sign Up to like & get
recommendations! Published in 2019 at "Hematological Oncology"

DOI: 10.1002/hon.137_2630

Abstract: (95% CI: 5.0 days-1.9 months; Fig. 1). At a median follow up of 4.15 years 6 patients treated at target dose were still alive and treatment-free, whereas the 13 patients treated at lower dose levels… read more here.

Keywords: novel multi; trial novel; action therapy; first human ... See more keywords
Photo by joshuafernandez from unsplash

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.

Sign Up to like & get
recommendations! Published in 2019 at "Vaccine"

DOI: 10.1016/j.vaccine.2019.02.024

Abstract: BACKGROUND We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional doses of a licensed rabies… read more here.

Keywords: cv8102; based adjuvant; immunogenicity; rna based ... See more keywords
Photo by nci from unsplash

PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.tps3107

Abstract: TPS3107Background: CX-072 is a novel Probody™ therapeutic (PbTx) targeting PD-L1. PbTx’s are fully recombinant antibody prodrugs designed to be converted to active antibodies by tumor-associated pr... read more here.

Keywords: probody; proclaim 001; trial assess; 001 first ... See more keywords
Photo by nci from unsplash

GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.15_suppl.2000

Abstract: 2000Background: The need for treatment personalization is obvious as every cancer is molecularly unique. In addition glioblastoma (GB) are immunologically regarded as resistant, “cold” tumor with f... read more here.

Keywords: trial highly; glioblastoma; 101 first; first human ... See more keywords